Irinotecan promising in some patients with stage III colon cancer
A subset of patients with stage III colon cancer had improved survival rates when treated with irinotecan-based therapy, according to a new study.
When added to the standard chemotherapy treatment, which is fluorouracil and leucovorin, adjuvant irinotecan therapy improved overall survival rates for patients with the CpG island methylator phenotype (CIMP). CIMP is seen in about 10% to 20% of colorectal cancers.
Patients with CIMP-negative tumors, however, exhibited significant harm from the addition of irinotecan. Their overall survival was 68% compared with 78% for those receiving the standard treatment alone. This study was published in Gastroenterology (2014; doi:10.1053/j.gastro.2014.05.009).
"Our results serve as an example that the molecular characterization of individual tumors may help to determine the most appropriate treatment for patients with colon cancer," said lead study author Stacey Shiovitz, MD, from the Department of Medicine, University of Washington, Seattle, Washington, and the clinical research division of Fred Hutchinson Cancer Research Center, also in Seattle. "Based on our findings, identification of a tumor's CIMP status should play a greater role in the clinical setting."
Researchers analyzed data from patients with stage III colon cancer randomly assigned to groups given fluorouracil and leucovorin or adjuvant irinotecan after surgery, from April 1999 through April 2001. Patients were followed for 8 years. Patients with CIMP-positive tumors demonstrated a trend toward improved overall survival when treated with irinotecan versus the standard treatment alone, 69% versus 56%, respectively. Results were most pronounced among patients with stage III CIMP-positive, mismatch repair intact (MMR-I) colon cancer.
No significant associations or interactions between CIMP and KRAS or BRAF mutations were observed, suggesting that the effectiveness of this treatment is not influenced by KRAS/BRAF mutation status.
"This analysis serves to increase our understanding of which subset of patients might benefit from irinotecan adjuvant therapy. This research is an important step in the medical community's work to classify tumors into groups that would result in optimized treatment strategies, thus delivering a higher level of personalized care to patients," said Shiovitz.
Future studies are needed to better understand the origin of the CIMP phenotype and to test these findings in a larger subset.